Aberrant DNA methylation in malignant melanoma

Carolina Schinke, Yongkai Mo, Yiting Yu, Kathy Amiri, Jeff Sosman, John M. Greally, Amit K. Verma

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma.

Original languageEnglish (US)
Pages (from-to)253-265
Number of pages13
JournalMelanoma Research
Volume20
Issue number4
DOIs
StatePublished - Aug 2010

Fingerprint

DNA Methylation
Melanoma
Epigenomics
Methylation
Gene Expression
Therapeutics
Genes
Neoplasms

Keywords

  • decitabine
  • epigenetics
  • hypermethylation
  • melanoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Dermatology
  • Medicine(all)

Cite this

Aberrant DNA methylation in malignant melanoma. / Schinke, Carolina; Mo, Yongkai; Yu, Yiting; Amiri, Kathy; Sosman, Jeff; Greally, John M.; Verma, Amit K.

In: Melanoma Research, Vol. 20, No. 4, 08.2010, p. 253-265.

Research output: Contribution to journalArticle

Schinke, Carolina ; Mo, Yongkai ; Yu, Yiting ; Amiri, Kathy ; Sosman, Jeff ; Greally, John M. ; Verma, Amit K. / Aberrant DNA methylation in malignant melanoma. In: Melanoma Research. 2010 ; Vol. 20, No. 4. pp. 253-265.
@article{741dd4c9d03f43b0a1d85133df8fba14,
title = "Aberrant DNA methylation in malignant melanoma",
abstract = "Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma.",
keywords = "decitabine, epigenetics, hypermethylation, melanoma",
author = "Carolina Schinke and Yongkai Mo and Yiting Yu and Kathy Amiri and Jeff Sosman and Greally, {John M.} and Verma, {Amit K.}",
year = "2010",
month = "8",
doi = "10.1097/CMR.0b013e328338a35a",
language = "English (US)",
volume = "20",
pages = "253--265",
journal = "Melanoma Research",
issn = "0960-8931",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Aberrant DNA methylation in malignant melanoma

AU - Schinke, Carolina

AU - Mo, Yongkai

AU - Yu, Yiting

AU - Amiri, Kathy

AU - Sosman, Jeff

AU - Greally, John M.

AU - Verma, Amit K.

PY - 2010/8

Y1 - 2010/8

N2 - Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma.

AB - Malignant melanoma remains one of the most deadly human cancers with no effective cures for metastatic disease. The poor efficacy of current therapy in advanced melanoma highlights the need for better understanding of molecular mechanisms contributing to the disease. Recent work has shown that epigenetic changes, including aberrant DNA methylation, lead to alterations in gene expression and are as important in the development of malignant melanoma as the specific and well-characterized genetic events. Reversion of these methylation patterns could thus lead to a more targeted therapy and are currently under clinical investigation. The purpose of this review is to compile recent information on aberrant DNA methylation of melanoma, to highlight key genes and molecular pathways in melanoma development, which have been found to be epigenetically altered and to provide insight as to how DNA methylation might serve as targeted treatment option as well as a molecular and prognostic marker in malignant melanoma.

KW - decitabine

KW - epigenetics

KW - hypermethylation

KW - melanoma

UR - http://www.scopus.com/inward/record.url?scp=77954661329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954661329&partnerID=8YFLogxK

U2 - 10.1097/CMR.0b013e328338a35a

DO - 10.1097/CMR.0b013e328338a35a

M3 - Article

C2 - 20418788

AN - SCOPUS:77954661329

VL - 20

SP - 253

EP - 265

JO - Melanoma Research

JF - Melanoma Research

SN - 0960-8931

IS - 4

ER -